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Cranio-spinal CTV included the entire cranio-spinal axis; the 
related PTV was a uniform expansion of the CTV with a 
margin of 3 mm for brain and 7 mm for spinal cord. The boost 
CTV was the tumour bed; the boost PTV was generated by a 
margin of 3 mm. Organs-at-risk (OARs) were: the brain, eyes, 
lenses, optical nerves, optic chiasm, thyroid, pituitary, heart, 
lungs, liver, kidneys, and gonads. Non-target tissue was 
defined as the body outline excluding the PTVs and the OARs. 
For each patient, 2 treatment plans (cranio-spinal plus 
boost), VMAT and IMRT, were generated, using 6 MV photons 
and 2 isocenters at the same source-axis-distance and shifted 
apart according to patient's length. For VMAT 2 coplanar 
complete arcs, and for IMRT 5 coplanar beams evenly 
distributed were used for each isocenter.  
DVHs and treatment delivery data (MU and number of 
segments) from VMAT and IMRT plans were compared.  
Results: Fig. 1. Dose distribution comparison between VMAT 
(1a) and IMRT (1b), in axial and sagittal views (cranio-spinal 
plus boost). The dose is displayed as: orange: 53.01 Gy (95% 
of boost dose of 55.8 Gy), green: 22.23 Gy (95% of CSI dose of 
23.4 Gy), dark blue: 5 Gy.  
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Table1. Dosimetric comparison between VMAT, IMRT and 
dose limits for paediatric patients.PTV: Planning-Target-
Volume; HI: homogeneity index HI = D2%/D98%; CI: 
conformity index. 
 
 
The low dose spread to non-target tissue was lower and 
statistically significant (p=0.00625) for VMAT plans (V5Gy of 
37.37% for VMAT vs. 40.69% for IMRT), and showed an inverse 
linear dependence with the patient antero-posterior 
diameter at xyphoid level. 
Fig. 2. Relation between non-target tissue V5Gy and patient 
antero-posterior diameter, for supine and prone positions.  
 
 
 
Analysis of treatment delivery data showed that IMRT plans 
had about 40% less MU than VMAT (p=0.00001).  
 
Conclusions: VMAT and IMRT produce similar dose 
distribution for CSI of paediatric patients.None of them was 
able to reduce the doses to eyes, lens, cochleas, pituitary 
and brain to the dose limits for paediatric patients. Thus, 
both carry similar increased risk of neurocognitive decline, 
growth, hearing loss, vision impairment and secondary 
malignancies. Further research is needed to assess the 
clinical benefit of novel radiotherapy modalities. 
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Purpose/Objective: Progressive diffuse intrinsic pontine 
glioma (DIPG) is a clinical challenge and the most common 
death cause among pediatric brain tumor patients. Recent 
reports of cases of progressive DIPG with re-irradiation have 
shown a better outcome than any other treatment modality. 
In our service, we have been performing re-irradiation of 
progressive DIPG patients since 2013. In order to evaluate the 
preliminary results of this treatment strategy, we have 
retrospectively reviewed patients' chart data. 
Materials and Methods: This is an observational retrospective 
evaluation of a small cohort of four cases of pediatric 
patients with progressive DIPG treated with re-iradiation 
after previous treatment with radiation therapy and 
chemotherapy. It has received approval by our institutional 
review board with a waiver of informed consent for these 
patients because they had already deceased. All patients 
were treated in our institution (Pediatric Cancer Center) and 
received radiation therapy (RT) at CRIO (Centro Regional 
Integrado de Oncologia) a partner institution. The authors 
were in charge of the treatment of the patients. This report 
complies with CARE guidelines for case reports.  
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Results: Four children, female, ages 3.7, 5.2, 5.4 and 12 
years (patients 1 to 4), were diagnosed between February 
and July 2013 with DIPG. They were treated initially with 
radiochemotherapy. Patients 1, 2 and 4 have received 54 Gy 
of conformal RT including the primary tumor with margins. 
The third patient initiated RT as scheduled but had to 
interrupt it after the administration of 14.4 Gy due to a 
severe CNS infection (ventriculitis). RT was withheld until the 
event of clinical progression. Patients 2 and 4 received 
weekly carboplatin and vincristine as first line treatment. 
Patient 1 received temozolomide during and after RT. Patient 
3 was scheduled to receive high dose chemotherapy 
(cisplatin, vincristine and etoposide) during RT, but only 
completed the first cycle of the planned treatment. The 
progression-free survival after first line treatment was 10.3, 
6.7, 10.4 and 15.1 months. The doses of the re-irradiation 
were 45, 27, 45 and 18 Gy. Second-line chemotherapy was 
temozolomide for patients 1 and 4. Overall survival after re-
irradiation was 4.9, 4.2, 9.9 and 4.4 months. All patients had 
some degree of clinical benefit with re-irradiation, ranging 
from stopping steroids to minor symptom amelioration. 
Patients 2 and 4 had stable disease in image evaluation (MRI) 
after re-irradiation. The other patients were not evaluated 
with imaging. No patient had side effects related to re-
irradiation therapy. 
Conclusions: In this small case series report, re-irradiation 
for pediatric patients with progressive DIPG was feasible, 
safe, and associated with clinically meaningful results. As no 
other treatment modality can offer any possibility of 
response in this subset of patients, re-irradiation is a good 
candidate to be rapidly incorporated into routine clinical 
practice for progressive DIPG. A phase I-II trial should be 
planned to test the best dose range.  
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Purpose/Objective: The number of elderly people with 
cervical cancer is increasing and elderly patients have age-
related problems related to morbidity. In this study, we 
evaluate pelvic radiation treatment tolerance of elderly 
cervical cancer patients treated with concurrent 
chemoradiotherapy.  
Materials and Methods: We retrospectively reviewed electric 
medical records of 102 cervical cancer patients treated with 
chemoradiotherapy from April 2007 to Feb 2014. Patients 
received concurrent radiation therapy with weekly cisplatin 
chemotherapy followed by intracavity radiotherapy. Patients 
were divided into nonelderly (ages < 70) (n = 65) and elderly 
(ages > 70) (n = 37) groups. The patient Charson comorbidity 
index, treatment factor and clinical parameters including 
pretreatment complete blood count were analyzed to 
identify treatment tolerance.  
Results: Elderly patients had a higher comorbidity index than 
younger patients. (p = 0.002) But, there was no significant 
difference in treatment compliance (treatment interruption ≥ 
2 days) to chemoradiotherapy between two groups. There 
was no significant difference in treatment related toxicity 
between the groups. In univariate and multivariate analyses, 
comorbidity index was significantly associated with 
treatment compliance (p = 0.011).  
Conclusions: Comorbidity index rather than age would be a 
predictive factor for pelvic treatment tolerance. Personalized 
supportive care considering patient status for cervical cancer 
is needed during treatment.  
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Purpose/Objective: Oncological treatment of older 
population has many unresolved questions, mainly due to low 
accrual of these patients into clinical trials. However, in 
everyday clinical practice an oncologist has to decide which 
treatment-guidelines are applicable for these patients. In this 
study, the treatment approach and rate of complications in 
elderly patients with locally advanced rectal cancer were 
evaluated.  
Materials and Methods: A retrospective review of medical 
records of patients who were treated with a curative intent 
for rectal carcinoma between January-2005 and December-
2011 was conducted. Two age groups were included: group-A: 
> 80-years (the study group), group-B: 65-75 years-old (a 
control group). Extracted data included demographics, co-
morbidities, treatment protocols, toxicity and time of death. 
Results: A total of 71 patients (35-group A, 36-group B) were 
included. Mean age was group A=83.5-years (range 80-96) and 
group B=70-years (range 65-75).The groups were well-
balanced with regards to co-morbidities, blood-tests, TRUS T-
stage, tumor location and timing of surgery with regards to 
radiotherapy. Radiotherapy without chemotherapy was given 
to 69% of group A compared to 22% of patients in group B 
(p<0.0001). During radiotherapy there were no significant 
difference with regards to early discontinuation, treatment 
interruptions, total dose and treatment toxicity. This 
treatment was given during planned hospitalization in 26% in 
group A compared to 5.4% in group B (p=0.022). 
Chemotherapy was given in 31% of patients in group A: 82% of 
initial 5-fluorouracil dose was less than 75%; additional dose-
reduction was needed in 63%, and in 45% of the patients the 
treatment was prematurely stopped, only 2 patients received 
capecitabine. In group B more patients received 
chemotherapy (78%), and in 93% of the patients the initial 
dose was more than 75%. There were no significant 
differences in a type of surgical procedure. The median 
survival in group A was 36.4 months and 31.2 months in group 
B (p=0.49). The mortality rate was 77% and 54% (p=0.05) 
respectively.  
Conclusions: Old age has significant implications on the 
treatment decision for initial chemotherapy-dose and need of 
